Investee Company Update: Little Green Pharma Ltd
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your SEED notes
SEED Innovations Ltd, the AIM-quoted company investment company providing shareholders with exposure to early-stage health, wellness and medical cannabis companies to which, in normal circumstances, they have limited access to, is pleased to note an announcement released on the ASX by its portfolio company, Little Green Pharma Ltd ('LGP').
The Company owns 7,324,796 ordinary shares in LGP representing 2.44% of LGP's issued share capital.
Quarterly Activities Report and Appendix 4C
Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to provide its activities report and Appendix 4C for the quarter ending 30 September 2023.
Highlights
- Revenue $6.2 million (unaudited) and cash receipts $6.6 million
- Paul Long appointed CEO as Fleta Solomon transitions to executive director
- France post-trial access pathway proposed amendment published
- Reset mind sciences expected to be demerged by end of 2023
- FY2023 R&D claim lodged for $5.5 million with funds expected in coming quarters
- Five new LGP products released
- Global quest initiative study launched
- Clinically meaningful quest 3-month results published
- Reset cultivates first psilocybin mushrooms and imports first psilocybin shipment
- LGP introduces industry first trial box product
- EU pharmacopeia cannabis monograph announced
- Cash in bank $6.2 million
The announcement in full can be accessed from the following link: https://www.investlittlegreenpharma.com/site/showdownloaddoc.aspx?AnnounceGuid=a0ba0a4d-814d-474f-a5c4-ccfc6cb95279
About Little Green Pharma
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.